Andrew D J Pearson, Sara Federico, Susanne A Gatz, Michael Ortiz, Giovanni Lesa, Nicole Scobie, Ioannis Gounaris, Susan L Weiner, Brenda Weigel, T J Unger, Elizabeth Stewart, Malcolm Smith, Emily K Slotkin, Gregory Reaman, Alberto Pappo, Karsten Nysom, Koen Norga, Joe McDonough, Lynley V Marshall, Donna Ludwinski, Franca Ligas, Dominik Karres, Marcel Kool, Thierry J Horner, Anton Henssen, Delphine Heenen, Douglas S Hawkins, Lia Gore, Julia Glade Bender, Sara Galluzzo, Elizabeth Fox, Teresa de Rojas, Barry R Davies, Jayeta Chakrabarti, Juliet Carmichael, Diana Bradford, Patricia Blanc, Ronald Bernardi, Sylvie Benchetrit, Korede Akindele, Gilles Vassal
DNA damage response inhibitors have a potentially important therapeutic role in paediatric cancers; however, their optimal use, including patient selection and combination strategy, remains unknown. Moreover, there is an imbalance between the number of drugs with diverse mechanisms of action and the limited number of paediatric patients available to be enrolled in early-phase trials, so prioritisation and a strategy are essential. While PARP inhibitors targeting homologous recombination-deficient tumours have been used primarily in the treatment of adult cancers with BRCA1/2 mutations, BRCA1/2 mutations occur infrequently in childhood tumours, and therefore, a specific response hypothesis is required...
September 2023: European Journal of Cancer